Level Biotechnology Cash Flow-to-Debt Ratio
Level Biotechnology cash flow-to-debt ratio. Level Biotechnology (3118) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of NT$11.81 Million could theoretically repay 0% of its total liabilities (NT$237.03 Million) in one year. Check 3118 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Level Biotechnology (2017–2024)
Cash flow-to-debt ratio of Level Biotechnology from 2017 to 2024. Historical debt coverage capacity for Level Biotechnology across 8 annual periods. Check Level Biotechnology (3118) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Level Biotechnology Cash Flow-to-Debt Ratio by Year (2017–2024)
Level Biotechnology cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Level Biotechnology. For the full cash flow conversion analysis, see 3118 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.24x | NT$64.10 Million | NT$267.19 Million | ▼ -6.7% |
| 2023 | 0.26x | NT$70.21 Million | NT$273.20 Million | ▲ +6.7% |
| 2022 | 0.24x | NT$65.07 Million | NT$270.13 Million | ▼ -62.5% |
| 2021 | 0.64x | NT$155.95 Million | NT$242.78 Million | ▲ +88.0% |
| 2020 | 0.34x | NT$83.23 Million | NT$243.56 Million | ▼ -25.9% |
| 2019 | 0.46x | NT$109.02 Million | NT$236.43 Million | ▲ +212.8% |
| 2018 | 0.15x | NT$26.77 Million | NT$181.60 Million | ▼ -56.6% |
| 2017 | 0.34x | NT$71.29 Million | NT$210.03 Million | — |